BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 20, 2026
Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
Musculoskeletal, BioWorld Science RSS Feed RSS

Aryl C-glycosides as selectin inhibitors jointly developed by Sankyo, Glycomed

Nov. 5, 1998

Potent and selective COX-2 inhibitors from Merck Frosst useful for inflammation

Nov. 4, 1998

Korean laboratory prepares new series of TNF-alpha inhibitors

Nov. 4, 1998

FDA approves, Immunex launches breakthrough treatment for RA

Nov. 3, 1998

Orally active collagenase inhibitor Ro-32-3555 shows potential for osteoarthritis Rx

Nov. 3, 1998

Preparation and use of TNF-alpha and MMP inhibitors described by Novartis

Nov. 3, 1998

Safety and efficacy of COX-2 inhibitor established in phase II trials

Nov. 2, 1998

Prosorba Column recommended for approval by FDA advisory panel

Nov. 2, 1998

Vertex and HMR initiate phase I clinical trial with HMR-3480/VX-740

Oct. 30, 1998

New COX-2 inhibitor scheduled for FDA advisory committee review in early December

Oct. 30, 1998
Previous 1 2 … 507 508 509 510 511 512 513 514 515 … 573 574 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing